Stockscreener 앱 받기
41.83
6.28%
2.47
전일 마감가:
$39.36
열려 있는:
$41.6
하루 거래량:
11.87M
Relative Volume:
1.07
시가총액:
$16.34B
수익:
$3.14B
순이익/손실:
$-3.36B
주가수익비율:
-4.7915
EPS:
-8.73
순현금흐름:
$-4.03B
1주 성능:
+21.95%
1개월 성능:
+39.95%
6개월 성능:
+30.47%
1년 성능:
+23.90%
1일 변동 폭
$40.55
$42.39
1주일 범위
$32.37
$42.39
52주 변동 폭
$22.28
$45.40
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
MRNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
41.83 | 15.38B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-12 | 개시 | Jefferies | Hold |
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
Moderna Shares Surge Amid Positive Earnings and Regulatory News - StocksToTrade
Moderna’s Market Gains as Revenue Projections Boost Investor Confidence - timothysykes.com
Moderna stock price pops 6% into the weekend — here’s what traders are watching next for MRNA - TechStock²
OVERSEA CHINESE BANKING Corp Ltd Sells 37,172 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna (NASDAQ:MRNA) Upgraded at Wall Street Zen - MarketBeat
Moderna Stock vs Competition: Who Wins? - Trefis
Weekly Market Update: Stocks Remain Flat as Consumer Defensives Rise and Financial Services Fall - morningstar.com
I Hope Moderna (MRNA) Posts Growth, Says Jim Cramer - Finviz
Moderna (NASDAQ:MRNA) Shares Gap UpStill a Buy? - MarketBeat
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026 - FinancialContent
Arbutus falls as patent dispute with Moderna hits EU snag - Seeking Alpha
Moderna's Q4 2025 Earnings: What to Expect - Barchart.com
Best Biotech Stocks To Keep An Eye OnJanuary 15th - MarketBeat
Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week? - Finviz
Analysts Set Expectations for Moderna FY2030 Earnings - MarketBeat
Non-covid mRNA Vaccine and Therapeutics Market Exclusive Report on the Latest Revenue and Future Scope - openPR.com
Aug Drivers: Is Moderna Inc a turnaround story2025 Trading Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
Moderna projects 10% growth next year; lifts outlook for year-end liquidity - MSN
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot - FinancialContent
Moderna (MRNA) Stock: Biotech Leader Surges 30% on Updated Guidance - Blockonomi
Moderna (MRNA) rockets 17% on strong preliminary FY25 results - MSN
Moderna (MRNA) Rockets 17% on Strong Preliminary FY25 Results - Insider Monkey
Moderna Inc.: From Pandemic Phenomenon to mRNA Platform Powerhouse - AD HOC NEWS
Building Companies Like Experiments: The Flagship Pioneering Model - Citeline News & Insights
Trending tickers: Nvidia, Intel, Moderna, BP and Vistry - Yahoo Finance UK
Moderna (MRNA) Stock: Biotech Breaks Out With 30% Rally in 2026 - CoinCentral
Moderna 2026 at JPM 2026: Projects $1.9B Revenue and Eyes Vaccine Approvals - geneonline.com
Intel, Moderna, Adobe, BitMine Immersion And Strategy: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target - BioPharma Dive
Moderna Eyes Higher Revenue and Strategic Approvals at J.P. Morgan Event - timothysykes.com
Adobe stock downgraded, Moderna surges on upbeat guidance - Yahoo Finance
Moderna (NASDAQ:MRNA) Shares Up 7.1%Still a Buy? - MarketBeat
Moderna rallies after projecting better-than-expected 2025 sales - Sherwood News
Why Moderna Stock Strength Is Only Beginning: Technical Analysis - Barron's
Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday? - Benzinga
Moderna (MRNA) Shares Surge by Nearly 13% - GuruFocus
Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday - Benzinga
Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next - TechStock²
Moderna jumps 12% after 2025 projections - breakingthenews.net
Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story (MRNA) - Seeking Alpha
Moderna updates 2025 outlook and highlights pipeline progress - The Globe and Mail
Moderna says possible allergic reactions to Covid-19 vaccine under investigation - The Daily Star
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - The Providence Journal
Moderna chair says US assault on science is just beginning - The Daily Gazette
Commonwealth Fusion Systems Appoints Stephane Bancel, Moderna CEO, to Its Board of Directors - energynews
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape - FinancialContent
Moderna Chair Says US Assault on Science Is Just Beginning - Bloomberg.com
Commonwealth Fusion Systems Appoints Stephane Bancel To Board - citybiz
Moderna expects 2025 revenue of $1.9B, above guidance - Proactive financial news
Aug Decliners: Should you avoid Moderna Inc stock right now2025 Biggest Moves & High Win Rate Trade Alerts - baoquankhu1.vn
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
모더나 주식 (MRNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| AFEYAN NOUBAR | Director |
Dec 11 '25 |
Sale |
29.48 |
23,853 |
703,306 |
3,924 |
| Bancel Stephane | Chief Executive Officer |
Dec 11 '25 |
Option Exercise |
10.90 |
688,073 |
7,499,996 |
6,181,970 |
4.73%
0.92%
자본화:
|
볼륨(24시간):